Edition:
United Kingdom

Regenxbio Inc (RGNX.OQ)

RGNX.OQ on NASDAQ Stock Exchange Global Select Market

27.55USD
8:59pm GMT
Change (% chg)

$0.45 (+1.66%)
Prev Close
$27.10
Open
$27.30
Day's High
$28.90
Day's Low
$27.15
Volume
76,518
Avg. Vol
94,008
52-wk High
$36.35
52-wk Low
$16.30

Select another date:

Tue, Jan 23 2018

BRIEF-Regenxbio Enters Strategic Partnership With Fujifilm Diosynth Biotechnologies

* REGENXBIO ENHANCES GENE THERAPY MANUFACTURING CAPABILITIES BY ENTERING INTO STRATEGIC PARTNERSHIP WITH FUJIFILM DIOSYNTH BIOTECHNOLOGIES

BRIEF-Regenxbio And Avexis Announce Expansion Of Relationship For Spinal Muscular Atrophy treatments

* REGENXBIO AND AVEXIS ANNOUNCE EXPANSION OF RELATIONSHIP THROUGH AMENDED LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF TREATMENTS FOR SPINAL MUSCULAR ATROPHY

BRIEF-Regenxbio Provides Year-End 2017 Corporate Update

* - ‍ANTICIPATE INITIATING DOSING IN CLINICAL TRIALS FOR MPS I AND MPS II IN FIRST HALF 2018​

BRIEF-Regenxbio Announces IND Active For Phase I/II Trial Of RGX-121 To Treat Mucopolysaccharidosis Type II

* REGENXBIO ANNOUNCES IND ACTIVE FOR PHASE I/II TRIAL OF RGX-121 TO TREAT MUCOPOLYSACCHARIDOSIS TYPE II

BRIEF-Regenxbio reports third quarter financial results

* Regenxbio reports third quarter 2017 financial results and recent operational highlights

BRIEF-RTW Investments reports 5 pct passive stake in Regenxbio

* RTW Investments reports a 5 percent passive stake in Regenxbio Inc as of October 2, 2017 - SEC filing Source text for Eikon: (http://bit.ly/2xkVMYD) Further company coverage:

BRIEF-Regenxbio announces completion of dosing of first cohort in Phase I clinical trial of RGX-314 gene therapy for wet AMD

* Regenxbio announces completion of dosing of first cohort in Phase I clinical trial of RGX-314 gene therapy for wet AMD

BRIEF-Dimension Therapeutics says co's board determined proposal from Ultragenyx Pharmaceutical could reasonably be expected to lead to "superior proposal"​

* Dimension Therapeutics - ‍Dimension board determines proposal from Ultragenyx Pharmaceutical could reasonably be expected to lead to "superior proposal"​

BRIEF-Regenxbio to acquire Dimension Therapeutics

* Dimension Therapeutics Inc says ‍boards of directors of both companies have unanimously approved transaction​

Select another date: